Published: Jan. 1, 2024
Language: Английский
European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 288, P. 117382 - 117382
Published: Feb. 16, 2025
Language: Английский
Citations
1
The EPMA Journal, Journal Year: 2025, Volume and Issue: unknown
Published: April 10, 2025
Cancer drug resistance poses a significant challenge in oncology, primarily driven by cancer cell plasticity, which promotes tumor initiation, progression, metastasis, and therapeutic evasion many different cancers. Breast cancers (BCs) are prominent example of that, with an estimated 2.3 million new cases 670,000 BC-related deaths registered worldwide annually. Triple-negative BC is especially challenging for treatments demonstrating particularly aggressive disease course, early manifestation metastatic disease, frequent drug-resistant types, poor individual outcomes. Although chemosensitizing agents have been developed, their clinical utility oncology remains unproven. The mitogen-activated protein kinase (MAPK) pathway considered critical regulator intracellular extracellular signaling highly relevant both - genetic epigenetic modifications. Dysregulation the MAPK pathways plays role conferring chemoresistance BC. Contextually, targeting represents promising strategy overcoming enhancing efficacy anticancer treatment. On other hand, flavonoids, class phytochemicals, key modulators signaling. Flavonoids interact ERK, JNK, p38, ERK5 cascade present avenue developing novel anti-cancer therapies re-sensitizing treatment Compounds such as quercetin, kaempferol, genistein, luteolin, myricetin, EGCG, baicalein, baicalin, nobiletin, morin, delphinidin, acacetin, isorhamnetin, apigenin, silymarin, among others, identified specific signaling, exerting complex downstream effects cells increasing therewith suppressing growth aggressivity. These properties reflect mechanisms great relevance to overcome overall management. This article highlights corresponding provides clinically illustrations framework 3P medicine primary (protection individuals at high risk against health-to-disease transition) secondary care progression). 3PM novelty makes good use patient phenotyping stratification, predictive multi-level diagnostics, application Artificial Intelligence (AI) tools individualized interpretation big data all proposed cost-effective tailored profiles clear benefits patients advanced
Language: Английский
Citations
1
Journal of Molecular Structure, Journal Year: 2025, Volume and Issue: unknown, P. 141506 - 141506
Published: Jan. 1, 2025
Language: Английский
Citations
0
Phytochemistry Reviews, Journal Year: 2025, Volume and Issue: unknown
Published: March 11, 2025
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(18), P. 10066 - 10066
Published: Sept. 19, 2024
This study investigated the therapeutic potential of licochalcone D (LicoD), which is derived from Glycyrrhiza uralensis, for improving glucose metabolism in AML12 hepatocytes with high-glucose-induced insulin resistance (IR). Ultra-high-performance liquid chromatography–mass spectrometry revealed that LicoD content G. uralensis was 8.61 µg/100 mg ethanol extract (GUE) and 0.85 hot water extract. GUE enhanced consumption uptake, as well Glut2 mRNA expression, IR cells. These effects were associated activation receptor substrate/phosphatidylinositol-3 kinase signaling pathway, increased protein B α phosphorylation, suppression gluconeogenesis-related genes, such Pepck G6pase. Furthermore, promoted glycogen synthesis by downregulating phosphorylase. mitigated downregulated expression mitochondrial oxidative phosphorylation proteins activating PPARα/PGC1α pathway increasing DNA content. findings demonstrate options alleviating IR-induced metabolic disorders function.
Language: Английский
Citations
2
Published: Jan. 1, 2024
Language: Английский
Citations
0